

Manuscript Number: AI-D-16-00014R1

Title: IMPACT OF RHINITIS ON LUNG FUNCTION IN CHILDREN AND ADOLESCENTS WITHOUT ASTHMA.

Article Type: Original Articles

Keywords: ARIA. Lung function test. Rhinitis. Spirometry. Children. Adolescents. Asthma.

Corresponding Author: Dr. Ricardo José Saranz, MD

Corresponding Author's Institution: Clínica Universitaria Reina Fabiola

First Author: Ricardo José Saranz, MD

Order of Authors: Ricardo José Saranz, MD; Alejandro Lozano, MD, PhD; Antonio Valero, MD, PhD; Natalia A Lozano, MD; María P Bovina Martijena, MD; María F Agresta, MD; Luciano Ianiero, MD; Marina F Ponzio, MD, PhD

**Abstract:** **Background:** Subclinical spirometric abnormalities may be detected in patients with rhinitis without asthma, proportional to severity established by ARIA (Allergic Rhinitis and Its Impact on Asthma) guideline. A new criteria of rhinitis classification was recently validated according to ARIA modified (m-ARIA), which allow the discrimination between moderate to severe grades. The impact of rhinitis on lung function according to frequency and severity is unknown. **Objectives:** To investigate subclinical spirometric impairment in children and adolescents with allergic and non-allergic rhinitis without overt symptoms of asthma, according to the frequency and severity criteria of rhinitis classified by m-ARIA. **Methods:** An observational cross sectional study, including children and adolescents aged 5-18 years with allergic and non-allergic rhinitis without asthma. We analyzed the functional abnormalities and bronchodilator response with spirometry in relation to the grade of rhinitis established by m-ARIA using an adjusted logistic model. Value of  $p < 0.05$  was considered statistically significant. **Results:** We studied 189 patients; 22.2% showed spirometric abnormalities. Patients with persistent rhinitis had greater impairment of lung function compared to intermittent grade ( $p=0.026$ ). Lung functional impairment was more frequent in severe and moderate rhinitis than mild grade ( $p=0.005$ ) and was independent of the atopic status to both frequency ( $p=0.157$ ) and severity ( $p=0.538$ ). There was no difference in bronchodilator reversibility between groups ( $p>0.05$ ). **Conclusions:** Impaired lung function was associated with persistence and severity of rhinitis and there was not a significant difference between patients with moderate and severe rhinitis. The spirometric abnormality was demonstrated in patients with allergic and non-allergic rhinitis



# IMPACT OF RHINITIS ON LUNG FUNCTION IN CHILDREN AND ADOLESCENTS WITHOUT ASTHMA

## *Authors:*

Ricardo J. Saranz\*  
Alejandro Lozano\*  
Antonio Valero\*\*  
Natalia A. Lozano\*  
María del Pilar Bovina Martijena\*  
Fernanda Agresta\*  
Luciano Ianiero\*  
Marina F. Ponzio\*\*\*

## **Acknowledgements**

The authors would like to acknowledge the fellows in training Yanina Berardi and Ana Gabriela Sosa for their collaboration in the patients recruitment and to Eugenia Concari for her technical assistant.

\*Allergy and Immunology Division, Clínica Universitaria Reina Fabiola, Facultad de Medicina, Universidad Católica de Córdoba, Argentina.

\*\*Immunoal.le`rgia Respirato`ria Cli`nica i Experimental (IRCE), Institut d'Investigacions Biome`diques August Pi i Sunyer (IDIBAPS), Barcelona; Centro de Investigacio`n Biome`dica en Red en Enfermedades Respiratorias (CIBERES); Allergy Unit, Pneumology and Respiratory Allergy Hospital Clinic i Universitari, Barcelona, Spain.

\*\*\* Cátedra de Fisiología Humana, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.

---

Correspondence: Ricardo J. Saranz. Allergy and Immunology Division- Clínica Universitaria Reina Fabiola. Oncativo 1248 - X5004FHP- Córdoba, Argentina. TE: +54-351- 4142140  
e-mail: [rsaranz@arnet.com.ar](mailto:rsaranz@arnet.com.ar)

## Abstract

*Background:* Subclinical spirometric abnormalities may be detected in patients with rhinitis without asthma, proportional to severity established by ARIA (*Allergic Rhinitis and Its Impact on Asthma*) guideline. A new criteria of rhinitis classification was recently validated according to ARIA modified (m-ARIA), which allow the discrimination between moderate to severe grades. The impact of rhinitis on lung function according to frequency and severity is unknown.

*Objectives:* To investigate subclinical spirometric impairment in children and adolescents with allergic and non-allergic rhinitis without overt symptoms of asthma, according to the frequency and severity criteria of rhinitis classified by m-ARIA.

*Methods:* An observational cross sectional study, including children and adolescents aged 5-18 years with allergic and non-allergic rhinitis without asthma. We analyzed the functional abnormalities and bronchodilator response with spirometry in relation to the grade of rhinitis established by m-ARIA using an adjusted logistic model. Value of  $p < 0.05$  was considered statistically significant.

*Results:* We studied 189 patients; 22.2% showed spirometric abnormalities. Patients with persistent rhinitis had greater impairment of lung function compared to intermittent grade ( $p=0.026$ ). Lung functional impairment was more frequent in severe and moderate rhinitis than mild grade ( $p=0.005$ ) and was independent of the atopic status to both frequency ( $p=0.157$ ) and severity ( $p=0.538$ ). There was no difference in bronchodilator reversibility between groups ( $p>0.05$ ).

*Conclusions:* Impaired lung function was associated with persistence and severity of rhinitis and there was not a significant difference between patients with moderate and

1  
2  
3  
4 severe rhinitis. The spirometric abnormality was demonstrated in patients with allergic  
5  
6 and non-allergic rhinitis.  
7  
8  
9

10  
11 **Key words:** ARIA, classification, lung function test, rhinitis, spirometry.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

Rhinitis is a chronic inflammatory disease of the nasal mucosa, characterized by nasal congestion, rhinorrhea, sneezing, and nasal itching, which becomes relevant because of its high prevalence and the negative impact in the patients' quality of life (1-3).

The link between the upper and lower airways has been recognized since the beginning of the last century (4), but has been investigated in depth only in the last two decades, with the model of relationship between rhinitis and asthma (5,6). Epidemiological data indicate that over 80% of patients with asthma have rhinitis whereas asthma can affect up to 40% of patients with rhinitis; therefore, many authors have suggested the "one airway one disease" hypothesis as an expression of one indivisible anatomical and pathological entity (1,2,7,8). Based on this concept, the relationship between the upper and lower airway relies not only in their epidemiological interest but also in their pathophysiological and clinical interest; it also has direct therapeutic implications (6,9, 10).

The ARIA (*Allergic Rhinitis and Its Impact on Asthma*) guideline (1,2), has proposed a clinical classification of rhinitis based on the frequency and severity of symptoms. Patients who develop symptoms for less than four days a week or less than four consecutive weeks, correspond to intermittent rhinitis whilst the presence of symptoms for more than four days a week and over four consecutive weeks, qualifies as persistent rhinitis.

The severity is determined by four items established in the ARIA guideline: impairment in the school or work performance, daily activities, sleep disturbances and troublesome

1  
2  
3  
4 symptoms. It is considered mild when none of the items are affected and moderate to  
5  
6  
7 severe when one or more items are present (o-ARIA).

8  
9 The PREDIAL multicenter study (*Pediatric Allergic Rhinitis*) (11) has recently validated  
10  
11 a new classification of rhinitis modified from the original ARIA guideline (m-ARIA),  
12  
13 which allows to differentiate the moderate from the severe rhinitis. Thus, mild rhinitis has  
14  
15 no affected items, moderate rhinitis compromises one to three items and the severe form  
16  
17 includes patients with all of the parameters affected (12).  
18  
19  
20

21 New evidences have detected subclinical abnormalities in lung function in patients with  
22  
23 allergic and non-allergic rhinitis with no symptoms suggestive of asthma (13-18), in a  
24  
25 proportional way according to the original o-ARIA severity criteria (16) and with  
26  
27 increased responsiveness to a bronchodilator (19,20); these findings could be the  
28  
29 expression of a common disease that affects the entire respiratory tract.  
30  
31  
32

33 The impact of rhinitis on lung function is still unknown according to the new  
34  
35 classification of m-ARIA and considering frequency (intermittent-persistent) and severity  
36  
37 (mild, moderate and severe).  
38  
39  
40

41 The aim of this study was to examine spirometric abnormalities and its potential  
42  
43 bronchodilator reversibility in children and adolescents with allergic and non-allergic  
44  
45 rhinitis without asthma, and its relationship with the symptoms frequency and severity.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Materials and Methods

*Study Design:* observational, cross-sectional analytical study.

*Patients: Inclusion and exclusion criteria*

Children and adolescents, between 5 and 18 years old referred to the Allergy and Immunology Division of the Clínica Universitaria Reina Fabiola, Universidad Católica de Córdoba, Argentina, were recruited from December 30, 2011 to May 31, 2013. The main inclusion criteria was a clinical diagnosis of rhinitis based on the presence of two or more nasal symptoms (rhinorrhea, blocked nose, itching and / or sneezing). Patients with allergic and non-allergic rhinitis were consecutively included, according to the presence or absence of aeroallergens sensitivity (determined by skin prick tests) and classified according to the symptoms duration and severity (11,12).

The exclusion criteria were as follows:

- a. Prior history of asthma or equivalent symptoms (cough, dyspnea and / or wheezing and shortness of breathing).
- b. Acute or chronic upper and lower airways infection.
- c. Anatomic nasal disorders, nasal polyposis, septum deviation, etc.
- d. Previous or current use of allergen-specific immunotherapy (subcutaneous or sublingual).
- e. Use of intranasal or systemic steroids, antihistamines, leukotriene antagonists and alpha-adrenergic (nasal or systemic) during the last four weeks.
- g. Active smokers and / or exposed to cigarette smoke at home.



### *Classification of rhinitis*

Was established according to the m-ARIA criteria (11,12). According to duration of the symptoms, patients with less than four days a week or less than four consecutive weeks were classified as suffering from intermittent rhinitis; the presence of symptoms for more than four days a week and over four consecutive weeks was considered as persistent rhinitis. The rhinitis severity was determined according to the number of affected items (limitations in school performance and daily activities, sleep disturbance or the existence of troublesome symptoms) as mild (no affected items), moderate (one to three quality of life items compromised) and severe (four affected items).

Despite the fact that ARIA guidelines are developed for allergic rhinitis, the Global Allergy and Asthma European Network suggested to classify non-allergic rhinitis with similar criteria than allergic rhinitis (21). Therefore we classified patients with non-allergic rhinitis according to the same definitions used for the allergic ones in terms of duration and severity of symptoms. (21,22).

### *Studied variables*

Age, gender, body mass index (BMI) and duration of rhinitis were considered. Spirometry and allergen skin prick test were performed.

The duration of rhinitis was established by the difference between the age of onset of the symptoms and the child age at the moment of diagnosis. The percentage of life affected was the result of the following equation:  $[\text{diagnosis age} - \text{age of onset} / \text{diagnoses age}] \times 100$ .

#### *Skin prick test*

For the skin prick tests a standardized panel was used with the following allergens: house dust mites (*Dermatophagoides pteronyssinus*, *Dermatophagoides farinae*, *Blomia tropicalis*), fungi (*Alternaria sp*, *Aspergillus sp*, *Cladosporium*, *Mucor*, *Rhizopus*, *Penicillium*), dog, cat and pollens from trees and grasses mix, *Compositae* mix (Alergo-Pharma®, Buenos Aires, Argentina). Histamine hydrochloride (10mg/dl) and sterile saline solution 0.9% were used as positive and negative controls. All tests were performed in the anterior forearm, using a Pricker type lancet (Diater Laboratories ®, Buenos Aires, Argentina) and readed after fifteen minutes using a millimeter rule. A wheal diameter  $\geq 3$  mm was considered as a positive reaction (23). The existence of one or more positive skin tests to allergens was associated with allergic rhinitis; his absence was compatible with a non-allergic rhinitis phenotype.

#### *Lung function test and bronchodilatador response*

A flow volume loop was performed using a Vitalograph ® 2120 UK spirometer, according to international standards of the American Thoracic Society / European Respiratory Society (ATS / ERS) (24). Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second of the FVC (FEV1), coefficient FEV1 / FVC and Forced Expiratory Flow between 25% and 75% of FVC (FEF 25-75 %) were recorded; the values were calculated by the software program included in the device, according to the predicted values of Knudson (25). Abnormal values were considered as those lower to 80% for the first three parameters and 65% for FEF 25-75% in relation to the normal predictive values (26).

1  
2  
3  
4 A bronchodilatador response was measured after the administration of 200 µg salbutamol  
5  
6 (Ventolin ®, GlaxoSmithKline) and expressed as positive when an improvement in FEV1  
7  
8  $\geq 12\%$  compared to baseline pre-bronchodilator values were obtained (26).  
9

10  
11 The best of three baseline and three post- bronchodilator measurements was chosen,  
12  
13 meeting the criteria for acceptability and reproducibility according to ATS / ERS (24).  
14

15  
16 Skin tests with allergens and spirometry were performed by the same operator without  
17  
18 knowledge of any of the studied variables. To avoid circadian variations, all studies were  
19  
20 conducted between 9 and 12 a.m.  
21

### 22 23 *Ethical aspects*

24  
25 This research protocol was approved by the Institutional Ethics Committee (CIEIS) of the  
26  
27 Clínica Universitaria Reina Fabiola, Facultad de Medicina, Universidad Católica de  
28  
29 Córdoba, Argentina, and in accordance to the guidelines of the Helsinki Declaration of  
30  
31 Good Clinical Practices and in agreement with the Province of Córdoba (Argentina) laws  
32  
33 for research on humans (# 9694/09). Informed consent for all interventions and the use of  
34  
35 data was requested to all patients, and confidentiality is guaranteed under national laws  
36  
37 for the protection of personal data (#25326/00). The authors declare no conflicts of  
38  
39 interest.  
40  
41  
42  
43  
44

### 45 46 *Statistical analysis*

47  
48 Analysis of the occurrence of impaired lung function (whatever their origin), the  
49  
50 involvement in each one of the respiratory parameters and the positive bronchodilator  
51  
52 response in relation to the severity of rhinitis, was performed by adjusting a logistic  
53  
54 model. The model included severity and duration of rhinitis as variables, and sex, age,  
55  
56 weight, height, BMI, atopy, family history of allergy, rhinitis duration and percentage of  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 life affected as co-variables. The purpose of including these co-variables was to eliminate  
5  
6 possible confounding effects to the severity of rhinitis. A significance level of 5% was  
7  
8 considered to establish statistical significance. To adjust for these models the function  
9  
10 glmer from lme4 library (27) of R was used (28), implemented under InfoStat software  
11  
12 interface (29).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Results

One hundred eighty nine children and adolescents, aged 5 to 18 years old, were included (106 males; 56%); the demographic and general characteristics distributed according to frequency and severity of rhinitis are shown in Tables 1 and 2.

In 42 of 189 patients (22.2%) at least one impaired lung function parameter was detected. FEV1 and FEV1 / FVC index were most frequently affected in 20 patients (10.6%), either alone or combined with another spirometric parameter, whilst FEF 25-75% was altered in 18 patients (9.5%).

The analysis also demonstrated that patients with persistent rhinitis had a greater impairment of lung function than those patients with intermittent rhinitis ( $p = 0.026$ ) (Table 3).

Patients with moderate and severe rhinitis have more functional lung impairment compared to patients with rhinitis in mild grade ( $p = 0.005$ ); however, no significant differences were detected among the first two (Table 3). The spirometric impairment was independent of atopic status for both frequency ( $p = 0.157$ ) and severity ( $p = 0.538$ ), and no differences were found in the bronchodilator response between groups (Table 3).

## Discussion

In the present study, differences in pulmonary function impairment were studied, considering the duration (intermittent-persistent) and severity (mild, moderate and severe) of rhinitis according to the m-ARIA criteria (11,12).

Some research have detected subclinical abnormalities in lung function in patients with rhinitis with no evidence of clinical asthma (13-17); in a previous study (17), we demonstrated that at least one altered respiratory function parameter was found in one quarter of patients with allergic rhinitis and that the FEV1/ FVC ratio was the most commonly affected parameter, either alone or combined with other functional measures. Our present findings confirms previous evidence that a high percentage of children and adolescent with rhinitis show some impairment in spirometric parameters, because 22.2% of the patients with allergic and non-allergic rhinitis, but without asthma, showed this alteration. Patients with persistent rhinitis had a higher functional respiratory impairment than those with intermittent rhinitis. Likewise, those rated as moderate and severe presented a greater lung impairment than those classified as mild, although no significant differences were detected between them.

A single study assessed lung function in relation to the severity of rhinitis in patients without asthma. Mohammad et al. (16) demonstrated in a group of young adult patients with allergic rhinitis, an impairment of the lung function that were proportional to the degree of rhinitis classified by the original ARIA guide. The moderate-severe persistent degree had a significantly greater bronchial involvement than the intermittent mild and moderate-severe and mild persistent (16). Other studies showed changes in lung function and bronchial hyperreactivity (BHR) in different patient populations with persistent

1  
2  
3  
4 rhinitis showing moderate and severe symptoms (18,30). BHR was more frequent in  
5  
6 patients with allergic rhinitis than in those with non-allergic rhinitis, and also that  
7  
8 persistency of rhinitis was a significant predictor of BHR (30). These findings highlights  
9  
10 the concept that a bronchial involvement is frequent in rhinitis, also in the absence of  
11  
12 overt asthmatic symptoms and are consistent with the hypothesis that the greater the  
13  
14 severity of rhinitis, the greater of the impact on lung function.  
15  
16  
17

18  
19 This ventilatory abnormality observed in children and adults with rhinitis in the absence  
20  
21 of asthmatic symptoms, is potentially reversible to the effects of a bronchodilator (19,20).  
22  
23 In adults with allergic rhinitis 8.4% of patients presented abnormal FEV<sub>1</sub> , 24.7 %  
24  
25 impaired FEF 25-75 % and 66.1% showed reversibility to bronchodilator (31) suggesting  
26  
27 that these alterations may indicate a “pre-asthmatic” status which can gradually evolve to  
28  
29 clinically demonstrated asthma with the progression of the "atopic march". This could  
30  
31 have therapeutic implications; however, in our study and considering the dissociated  
32  
33 conditions frequency and severity, we could not reproduce similar findings because the  
34  
35 reversibility obtained between groups was not significant. This is probably due because  
36  
37 the bronchodilator response was rated using not only patients presenting obstructive  
38  
39 defects but also those with alterations in FVC only.  
40  
41  
42  
43  
44

45  
46 The abnormality in lung function was independent of the atopy condition: whilst a higher  
47  
48 prevalence of allergic sensitization was observed in patients with severe rhinitis (Table  
49  
50 2), both phenotypes of rhinitis (allergic and non-allergic), showed similar functional  
51  
52 involvement. Chawes et al. (15) found similar impairment of the specific airway  
53  
54 resistance (sRaw), measured by whole body plethysmography in young children with  
55  
56 allergic and non-allergic rhinitis, although the former ones had significantly higher values  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 of exhaled nitric oxide (FeNO). These findings suggest that the impact of rhinitis on lung  
5  
6 function, in absence of asthma, would be proper to the condition of rhinitis and would not  
7  
8 be associated with its etiology.  
9

10  
11 Rhinitis in pediatric patients have a sub-clinical bronchial disease process that is  
12  
13 proportional to the magnitude of the disease, but the prognosis value of these findings is  
14  
15 not yet determined.  
16  
17

18  
19 It is shown that rhinitis is an independent risk factor for developing asthma (32-35) and  
20  
21 that the use of intranasal steroids can improve the functional defect in children with  
22  
23 allergic rhinitis without asthma (36), but no prospective research establish that patients  
24  
25 with rhinitis and impaired lung function have a higher risk of developing asthma.  
26  
27 Possibly this depends on common genetic factors for a possible progression of rhinitis to  
28  
29 asthma (37,38), which could have an initial sub-clinical expression in intra-thoracic  
30  
31 airway obstruction.  
32  
33

34  
35 These potential diagnostic, prognostic and therapeutic implications are sufficient reasons  
36  
37 to suggest that patients with rhinitis alone should be evaluated for asthma, based on their  
38  
39 clinical history, a careful chest examination and lung function assessment just as  
40  
41 proposed by the ARIA document (1,2). Our findings support the indication of spirometry  
42  
43 only in patients with persistent, moderate and severe degree of rhinitis, making  
44  
45 unnecessary the routine determination in patients with rhinitis classified as mild and  
46  
47 intermittent. This management strategy could contribute to financial savings for public  
48  
49 health, a suggestion which should be confirmed with studies involving a larger sample of  
50  
51 patients and reproducible results with other centers.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 Our study has the strength to confirm the asymptomatic impairment of lung function in  
5 children and adolescents with rhinitis, also observed by other authors (13-18,31) and that  
6 data analysis excluded potentially confounding variables. We recognize the limitations  
7 imposed by the clinical classifying degrees of rhinitis, because these can manifest  
8 variability over time and be influenced by subjectivity between operators.  
9

10  
11 In conclusion, this study highlights that impaired lung function appears in a substantial  
12 percentage of patients with allergic and non-allergic rhinitis. The involvement was more  
13 common in persistent, moderate to severe rhinitis, with no significant differences between  
14 these last two degrees of severity. The bronchial involvement was independent of the  
15 atopic status suggesting a link between the upper and lower airway diseases beyond the  
16 inflammation associated to the allergy status.  
17

18  
19 Our results also allow us to suggest that subjects with rhinitis and without asthma should  
20 be evaluated for their lung function, because this somehow can influence the course of  
21 the disease.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

1. Bousquet J, Van Cauwenberge P, Khaltaev N, ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. ARIA workshop report. *J Allergy Clin Immunol* 2001;108(5):S147-S334.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). *Allergy* 2008;63:S8-S160.
3. Gentile D, Bartholow A, Valovirta E, Scadding G, Skoner D. Current and future directions in pediatric allergic rhinitis. *J Allergy Clin Immunol: in Practice* 2013; 1:214-26.
4. Sluder G. Asthma as a nasal reflex. *JAMA* 1919;73:589-591.
5. Saranz RJ. Vías aéreas unidas e impacto recíproco entre rinosinusitis y asma. *Alergia Immunol Clin* 2002;19(3):71-77.
6. Cruz A. The “united airways” require an holistic approach to management. *Allergy* 2005; 60: 871-874.
7. Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. *Allergy* 2003; 58: 691-706.
8. Dixon AE. Rhinosinusitis and asthma: the missing link. *Curr Opin Pulmonary Med* 2009;15:19-24.
9. Kariyawasam HH, Rotiroti G. Allergic rhinitis, chronic rhinosinusitis and asthma: unravelling a complex relationship. *Curr Opin Otolaryngol Head Neck Surg* 2013; 21:79-86.
10. Agresta MF, Saranz RJ, Lozano A, Lonzano NA. Relación entre rinitis y asma: ¿Está todo dicho?. *Revista de la Facultad de Ciencias Médicas UNC* 2014; 71(2):111-121.
11. Montoro J, Del Cuvillo A, Mullol J, Molina X, Dávila I, Ferrer M, Jáuregui I, Sastre J, Valero A. Validation of the modified allergic rhinitis and its impact on asthma (ARIA)

- 1  
2  
3  
4 severity classification in allergic rhinitis children: the PEDRIAL study. *Allergy* 2012; 67:  
5  
6 1437-1442.  
7  
8  
9 12. Valero A, Ferrer M, Sastre J, Navarro AM, Monclus L, Marti-Guadaño E, Herdman M,  
10 Dávila I, del Cuvillo A, Colas C, Baro E, Antepara I, Alonso J, Mullol J. A new criterion  
11 by which to discriminate between patients with moderate allergic rhinitis and patients  
12 with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma  
13 severity items. *J Allergy Clin Immunol* 2007;120:359-65.  
14  
15  
16  
17  
18 13. Ciprandi G, Cirillo I, Pistorio A. Impact of allergic rhinitis on asthma: effects on  
19 spirometric parameters. *Allergy* 2008;63:255-260.  
20  
21  
22  
23  
24 14. Ciprandi G, Capasso M. Association of childhood perennial allergic rhinitis with  
25 subclinical airflow limitation. *Clin Exp Allergy* 2010; 40: 398-402.  
26  
27  
28  
29 15. Chawes BL. Upper and lower airway pathology in young children with allergic- and non-  
30 allergic rhinitis. *Dan Med Bull* 2011; 58(5):1-23.  
31  
32  
33  
34 16. Mohammad Y, Shaaban R, Ibrahim M, Ismail M. Lung function changes in non-  
35 asthmatic allergic rhinitis patients: a case series. *Prim Care Respir J* 2011; 20(4): 454-  
36 456.  
37  
38  
39  
40 17. Ianiero L, Saranz RJ, Lozano NA, Lozano A, Sasia LV, Ramírez M, Cuestas E. Analysis  
41 of the flow-volume curve in children and adolescents with allergic rhinitis without  
42 asthma. *Arch Argent Pediatr* 2013;111:322-327.  
43  
44  
45  
46 18. Jeffery CC, Bhutani M, Vliagoftis H, Wright ED, Seikaly H, Côté DW. Association  
47 between allergic rhinitis and asthma in a Northern Alberta cohort. *J Otolaryngol Head*  
48 *Neck Surg* 2013;42:58.  
49  
50  
51  
52  
53 19. Capasso M, Varricchio A, Ciprandi G. Impact of allergic rhinitis on asthma in children:  
54 effects on bronchodilation test. *Allergy* 2010; 65:264-268.  
55  
56  
57  
58 20. Ciprandi G, Signori A, Tosca MA, Cirillo I. Bronchodilation test in patients with allergic  
59 rhinitis. *Allergy* 2011; 66: 694–698.  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 21. Bousquet J, Fokkens W, Burney P, Durham SR, Bachert C, Akdis CA et al. Important  
5 research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper.  
6  
7 *Allergy* 2008; 63: 842-853.  
8  
9
- 10  
11 22. Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and  
12 perception of allergic and nonallergic rhinitis in Belgium. *Allergy* 2006; 61: 693-698.  
13  
14
- 15 23. Cox L, Williams B, Sicherer S, Oppenheimer J, Sher L, Hamilton R, Golden D. Pearls and  
16 pitfalls of allergy diagnostic testing: report from the American College of Allergy,  
17 Asthma and Immunology/ American Academy of Allergy, Asthma and Immunology  
18 Specific IgE Test Task Force. *Ann Allergy Asthma Immunol.* 2008;101:580-592.  
19  
20  
21  
22  
23
- 24 24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.  
25 Standardisation of spirometry. *Eur Respir J* 2005; 26:319-338.  
26  
27  
28
- 29 25. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume  
30 curve. Normal standards, variability, and effects of age. *Am Rev Respir Dis* 1976;113:  
31 587-600.  
32  
33  
34
- 35 26. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative  
36 strategies for lung function tests. *Eur Respir J* 2005; 26:948-968.  
37  
38  
39
- 40 27. Bates D, Maechler M, Bolker B and Walker S. (2013). lme4: Linear mixed-effects  
41 models using Eigen and S4. R package version 1.0-4. [http://CRAN.R-](http://CRAN.R-project.org/package=lme4)  
42 [project.org/package=lme4](http://CRAN.R-project.org/package=lme4)  
43  
44  
45
- 46 28. R Core Team (2013). R: A language and environment for statistical computing. R  
47 Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>.  
48  
49  
50
- 51 29. Di Rienzo J.A., Casanoves F., Balzarini M.G., Gonzalez L., Tablada M., Robledo C.W.  
52 InfoStat versión 2013. Grupo InfoStat, FCA, Universidad Nacional de Córdoba,  
53 Argentina. URL <http://www.infostat.com.ar>  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 30. Kim SW, Han DH, Lee SJ, Lee CH, Rhee CS. Bronchial hyperresponsiveness in pediatric  
5  
6 rhinitis patients: The difference between allergic and nonallergic rhinitis. *Am J Rhinol*  
7  
8 *Allergy* 2013;27:63-68.  
9
- 10  
11 31. Ciprandi G, Signori A, Tosca MA, and Cirillo I. Spirometric abnormalities in patients  
12  
13 with allergic rhinitis: indicator of an asthma march? *Am J Rhinol Allergy* 2011; 25:e181-  
14  
15 e185.  
16
- 17  
18 32. Scadding G, Walker A. Poor asthma control? – Then look up the nose. The importance of  
19  
20 co-morbid rhinitis in patients with asthma. *Prim Care Respir J* 2012; 21: 222-228.  
21
- 22  
23 33. Leynaert B, Bousquet J, Neukirch C, Korobaeff M, Liard R, Neukirch F. Perennial  
24  
25 rhinitis: an independent risk factor for asthma in nonatopic subjects. Results from the  
26  
27 European Community Respiratory Health Survey. *J Allergy Clin Immunol* 1999;104:301-  
28  
29 304.  
30
- 31  
32 34. Eriksson J, Bjerg A, Lötvall J, Wennergren G, Rönmark E, Torén K, Lundbäck B.  
33  
34 Rhinitis phenotypes correlate with different symptom presentation and risk factor patterns  
35  
36 of asthma. *Respir Med* 2011;105; 1611-1621.  
37
- 38  
39 35. Higuchi O, Adachi Y, Itazawa T, Ito Y, Yoshida K, Ohya Y, et al. Rhinitis has an  
40  
41 association with asthma in school children. *Am J Rhinol Allergy* 2013;27;22-25.  
42
- 43  
44 36. Kessel A. The impact of intranasal corticosteroids on lung function in children with  
45  
46 allergic rhinitis. *Pediatr Pulmonol* 2014; 49:932-937.  
47
- 48  
49 37. Bouzigon E, Forabosco P, Koppelman GH, Cookson WO, Dizier MH, Duffy DL, et al.  
50  
51 Meta-analysis of 20 genome wide linkage studies evidenced new regions linked to  
52  
53 asthma and atopy. *Eur J Hum Genet* 2010; 18:700-706.  
54
- 55  
56 38. Boulay MV, Morin A, Laprise C, Boulet LP. Asthma and rhinitis: what is the  
57  
58 relationship? *Curr Opin Allergy Clin Immunol* 2012,12:449-454.  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Abstract

*Background:* Subclinical spirometric abnormalities may be detected in patients with rhinitis without asthma, proportional to severity established by ARIA (*Allergic Rhinitis and Its Impact on Asthma*) guideline. A new criteria of rhinitis classification was recently validated according to ARIA modified (m-ARIA), which allow the discrimination between moderate to severe grades. The impact of rhinitis on lung function according to frequency and severity is unknown.

*Objectives:* To investigate subclinical spirometric impairment in children and adolescents with allergic and non-allergic rhinitis without overt symptoms of asthma, according to the frequency and severity criteria of rhinitis classified by m-ARIA.

*Methods:* An observational cross sectional study, including children and adolescents aged 5-18 years with allergic and non-allergic rhinitis without asthma. We analyzed the functional abnormalities and bronchodilator response with spirometry in relation to the grade of rhinitis established by m-ARIA using an adjusted logistic model. Value of  $p < 0.05$  was considered statistically significant.

*Results:* We studied 189 patients; 22.2% showed spirometric abnormalities. Patients with persistent rhinitis had greater impairment of lung function compared to intermittent grade ( $p=0.026$ ). Lung functional impairment was more frequent in severe and moderate rhinitis than mild grade ( $p=0.005$ ) and was independent of the atopic status to both frequency ( $p=0.157$ ) and severity ( $p=0.538$ ). There was no difference in bronchodilator reversibility between groups ( $p>0.05$ ).

*Conclusions:* Impaired lung function was associated with persistence and severity of rhinitis and there was not a significant difference between patients with moderate and

1  
2  
3  
4 severe rhinitis. The spirometric abnormality was demonstrated in patients with allergic  
5  
6 and non-allergic rhinitis.  
7  
8  
9

10  
11 **Key words:** ARIA, classification, lung function test, rhinitis, spirometry.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## Introduction

Rhinitis is a chronic inflammatory disease of the nasal mucosa, characterized by nasal congestion, rhinorrhea, sneezing, and nasal itching, which becomes relevant because of its high prevalence and the negative impact in the patients' quality of life (1-3).

The link between the upper and lower airways has been recognized since the beginning of the last century (4), but has been investigated in depth only in the last two decades, with the model of relationship between rhinitis and asthma (5,6). Epidemiological data indicate that over 80% of patients with asthma have rhinitis whereas asthma can affect up to 40% of patients with rhinitis; therefore, many authors have suggested the "one airway one disease" hypothesis as an expression of one indivisible anatomical and pathological entity (1,2,7,8). Based on this concept, the relationship between the upper and lower airway relies not only in their epidemiological interest but also in their pathophysiological and clinical interest; it also has direct therapeutic implications (6,9, 10).

The ARIA (*Allergic Rhinitis and Its Impact on Asthma*) guideline (1,2), has proposed a clinical classification of rhinitis based on the frequency and severity of symptoms. Patients who develop symptoms for less than four days a week or less than four consecutive weeks, correspond to intermittent rhinitis whilst the presence of symptoms for more than four days a week and over four consecutive weeks, qualifies as persistent rhinitis.

The severity is determined by four items established in the ARIA guideline: impairment in the school or work performance, daily activities, sleep disturbances and troublesome

1  
2  
3  
4 symptoms. It is considered mild when none of the items are affected and moderate to  
5  
6  
7 severe when one or more items are present (o-ARIA).

8  
9 The PREDIAL multicenter study (*Pediatric Allergic Rhinitis*) (11) has recently validated  
10  
11 a new classification of rhinitis modified from the original ARIA guideline (m-ARIA),  
12  
13 which allows to differentiate the moderate from the severe rhinitis. Thus, mild rhinitis has  
14  
15 no affected items, moderate rhinitis compromises one to three items and the severe form  
16  
17 includes patients with all of the parameters affected (12).  
18  
19  
20

21 New evidences have detected subclinical abnormalities in lung function in patients with  
22  
23 allergic and non-allergic rhinitis with no symptoms suggestive of asthma (13-18), in a  
24  
25 proportional way according to the original o-ARIA severity criteria (16) and with  
26  
27 increased responsiveness to a bronchodilator (19,20); these findings could be the  
28  
29 expression of a common disease that affects the entire respiratory tract.  
30  
31  
32

33 The impact of rhinitis on lung function is still unknown according to the new  
34  
35 classification of m-ARIA and considering frequency (intermittent-persistent) and severity  
36  
37 (mild, moderate and severe).  
38  
39

40 The aim of this study was to examine spirometric abnormalities and its potential  
41  
42 bronchodilator reversibility in children and adolescents with allergic and non-allergic  
43  
44 rhinitis without asthma, and its relationship with the symptoms frequency and severity.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Materials and Methods

*Study Design:* observational, cross-sectional analytical study.

*Patients: Inclusion and exclusion criteria*

Children and adolescents, between 5 and 18 years old referred to the Allergy and Immunology Division of the Clínica Universitaria Reina Fabiola, Universidad Católica de Córdoba, Argentina, were recruited from December 30, 2011 to May 31, 2013. The main inclusion criteria was a clinical diagnosis of rhinitis based on the presence of two or more nasal symptoms (rhinorrhea, blocked nose, itching and / or sneezing). Patients with allergic and non-allergic rhinitis were consecutively included, according to the presence or absence of aeroallergens sensitivity (determined by skin prick tests) and classified according to the symptoms duration and severity (11,12).

The exclusion criteria were as follows:

- a. Prior history of asthma or equivalent symptoms (cough, dyspnea and / or wheezing and shortness of breathing).
- b. Acute or chronic upper and lower airways infection.
- c. Anatomic nasal disorders, nasal polyposis, septum deviation, etc.
- d. Previous or current use of allergen-specific immunotherapy (subcutaneous or sublingual).
- e. Use of intranasal or systemic steroids, antihistamines, leukotriene antagonists and alpha-adrenergic (nasal or systemic) during the last four weeks.
- g. Active smokers and / or exposed to cigarette smoke at home.

*Classification of rhinitis*

1  
2  
3  
4 Was established according to the m-ARIA criteria (11,12). According to duration of the  
5  
6 symptoms, patients with less than four days a week or less than four consecutive weeks  
7  
8 were classified as suffering from intermittent rhinitis; the presence of symptoms for more  
9  
10 than four days a week and over four consecutive weeks was considered as persistent  
11  
12 rhinitis. The rhinitis severity was determined according to the number of affected items  
13  
14 (limitations in school performance and daily activities, sleep disturbance or the existence  
15  
16 of troublesome symptoms) as mild (no affected items), moderate (one to three quality of  
17  
18 life items compromised) and severe (four affected items).  
19  
20  
21  
22

23  
24 Despite the fact that ARIA guidelines are developed for allergic rhinitis, the Global  
25  
26 Allergy and Asthma European Network suggested to classify non-allergic rhinitis with  
27  
28 similar criteria than allergic rhinitis (21). Therefore we classified patients with non-  
29  
30 allergic rhinitis according to the same definitions used for the allergic ones in terms of  
31  
32 duration and severity of symptoms. (21,22).  
33  
34  
35

### 36 *Studied variables*

37  
38 Age, gender, body mass index (BMI) and duration of rhinitis were considered.  
39  
40 Spirometry and allergen skin prick test were performed.  
41  
42

43 The duration of rhinitis was established by the difference between the age of onset of the  
44  
45 symptoms and the child age at the moment of diagnosis. The percentage of life affected  
46  
47 was the result of the following equation:  $[\text{diagnosis age} - \text{age of onset} / \text{diagnoses age}] \times$   
48  
49  
50 100.  
51

### 52 *Skin prick test*

53  
54 For the skin prick tests a standardized panel was used with the following allergens: house  
55  
56 dust mites (*Dermatophagoides pteronyssinus*, *Dermatophagoides farinae*, *Blomia*  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 *tropicalis*),fungi (*Alternaria sp*, *Aspergillus sp*, *Cladosporium*, *Mucor*, *Rhizopus*,  
5 *Penicillium*), dog, cat and pollens from trees and grasses mix, *Compositae* mix (Alergo-  
6  
7 Pharma®, Buenos Aires, Argentina). Histamine hydrochloride (10mg/dl) and sterile  
8  
9 saline solution 0.9% were used as positive and negative controls. All tests were  
10  
11 performed in the anterior forearm, using a Pricker type lancet (Diater Laboratories ®,  
12  
13 Buenos Aires, Argentina) and readed after fifteen minutes using a millimeter rule. A  
14  
15 wheal diameter  $\geq 3$  mm was considered as a positive reaction (23). The existence of one  
16  
17 or more positive skin tests to allergens was associated with allergic rhinitis; his absence  
18  
19 was compatible with a non-allergic rhinitis phenotype.  
20  
21  
22  
23  
24

#### 25 26 *Lung function test and bronchodilatador response*

27  
28 A flow volume loop was performed using a Vitalograph ® 2120 UK spirometer,  
29  
30 according to international standards of the American Thoracic Society / European  
31  
32 Respiratory Society (ATS / ERS) (24). Forced Vital Capacity (FVC), Forced Expiratory  
33  
34 Volume in the first second of the FVC (FEV1), coefficient FEV1 / FVC and Forced  
35  
36 Expiratory Flow between 25% and 75% of FVC (FEF 25-75 %) were recorded; the  
37  
38 values were calculated by the software program included in the device, according to the  
39  
40 predicted values of Knudson (25). Abnormal values were considered as those lower to  
41  
42 80% for the first three parameters and 65% for FEF 25-75% in relation to the normal  
43  
44 predictive values (26).  
45  
46  
47  
48  
49

50 A bronchodilatador response was measured after the administration of 200 µg salbutamol  
51  
52 (Ventolin ®, GlaxoSmithKline) and expressed as positive when an improvement in FEV1  
53  
54  $\geq 12\%$  compared to baseline pre-bronchodilator values were obtained (26).  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 The best of three baseline and three post- bronchodilator measurements was chosen,  
5  
6 meeting the criteria for acceptability and reproducibility according to ATS / ERS (24).  
7

8  
9 Skin tests with allergens and spirometry were performed by the same operator without  
10  
11 knowledge of any of the studied variables. To avoid circadian variations, all studies were  
12  
13 conducted between 9 and 12 a.m.  
14

### 15 16 *Ethical aspects*

17  
18 This research protocol was approved by the Institutional Ethics Committee (CIEIS) of the  
19  
20 Clínica Universitaria Reina Fabiola, Facultad de Medicina, Universidad Católica de  
21  
22 Córdoba, Argentina, and in accordance to the guidelines of the Helsinki Declaration of  
23  
24 Good Clinical Practices and in agreement with the Province of Córdoba (Argentina) laws  
25  
26 for research on humans (# 9694/09). Informed consent for all interventions and the use of  
27  
28 data was requested to all patients, and confidentiality is guaranteed under national laws  
29  
30 for the protection of personal data (#25326/00). The authors declare no conflicts of  
31  
32 interest.  
33  
34  
35  
36  
37

### 38 39 *Statistical analysis*

40  
41 Analysis of the occurrence of impaired lung function (whatever their origin), the  
42  
43 involvement in each one of the respiratory parameters and the positive bronchodilator  
44  
45 response in relation to the severity of rhinitis, was performed by adjusting a logistic  
46  
47 model. The model included severity and duration of rhinitis as variables, and sex, age,  
48  
49 weight, height, BMI, atopy, family history of allergy, rhinitis duration and percentage of  
50  
51 life affected as co-variables. The purpose of including these co-variables was to eliminate  
52  
53 possible confounding effects to the severity of rhinitis. A significance level of 5% was  
54  
55 considered to establish statistical significance. To adjust for these models the function  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 glmer from lme4 library (27) of R was used (28), implemented under InfoStat software  
5  
6 interface (29).  
7  
8  
9

## 10 **Results**

11  
12 One hundred eighty nine children and adolescents, aged 5 to 18 years old, were included  
13 (106 males; 56%); the demographic and general characteristics distributed according to  
14  
15 frequency and severity of rhinitis are shown in Tables 1 and 2.  
16  
17  
18

19  
20 In 42 of 189 patients (22.2%) at least one impaired lung function parameter was detected.  
21  
22 FEV1 and FEV1 / FVC index were most frequently affected in 20 patients (10.6%),  
23  
24 either alone or combined with another spirometric parameter, whilst FEF 25-75% was  
25  
26 altered in 18 patients (9.5%).  
27  
28

29  
30 The analysis also demonstrated that patients with persistent rhinitis had a greater  
31  
32 impairment of lung function than those patients with intermittent rhinitis ( $p = 0.026$ )  
33  
34 (Table 3).  
35  
36

37 Patients with moderate and severe rhinitis have more functional lung impairment  
38  
39 compared to patients with rhinitis in mild grade ( $p = 0.005$ ); however, no significant  
40  
41 differences were detected among the first two (Table 3). The spirometric impairment was  
42  
43 independent of atopic status for both frequency ( $p = 0.157$ ) and severity ( $p = 0.538$ ), and  
44  
45 no differences were found in the bronchodilator response between groups (Table 3).  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Discussion

In the present study, differences in pulmonary function impairment were studied, considering the duration (intermittent-persistent) and severity (mild, moderate and severe) of rhinitis according to the m-ARIA criteria (11,12).

Some research have detected subclinical abnormalities in lung function in patients with rhinitis with no evidence of clinical asthma (13-17); in a previous study (17), we demonstrated that at least one altered respiratory function parameter was found in one quarter of patients with allergic rhinitis and that the FEV1/ FVC ratio was the most commonly affected parameter, either alone or combined with other functional measures.

Our present findings confirms previous evidence that a high percentage of children and adolescent with rhinitis show some impairment in spirometric parameters, because 22.2% of the patients with allergic and non-allergic rhinitis, but without asthma, showed this alteration. Patients with persistent rhinitis had a higher functional respiratory impairment than those with intermittent rhinitis. Likewise, those rated as moderate and severe presented a greater lung impairment than those classified as mild, although no significant differences were detected between them.

A single study assessed lung function in relation to the severity of rhinitis in patients without asthma. Mohammad et al. (16) demonstrated in a group of young adult patients with allergic rhinitis, an impairment of the lung function that were proportional to the degree of rhinitis classified by the original ARIA guide. The moderate-severe persistent degree had a significantly greater bronchial involvement than the intermittent mild and moderate-severe and mild persistent (16). Other studies showed changes in lung function and bronchial hyperreactivity (BHR) in different patient populations with persistent



1  
2  
3  
4 rhinitis showing moderate and severe symptoms (18,30). BHR was more frequent in  
5  
6 patients with allergic rhinitis than in those with non-allergic rhinitis, and also that  
7  
8 persistency of rhinitis was a significant predictor of BHR (30). These findings highlights  
9  
10 the concept that a bronchial involvement is frequent in rhinitis, also in the absence of  
11  
12 overt asthmatic symptoms and are consistent with the hypothesis that the greater the  
13  
14 severity of rhinitis, the greater of the impact on lung function.  
15  
16  
17

18  
19 This ventilatory abnormality observed in children and adults with rhinitis in the absence  
20  
21 of asthmatic symptoms, is potentially reversible to the effects of a bronchodilator (19,20).  
22  
23 In adults with allergic rhinitis 8.4% of patients presented abnormal FEV<sub>1</sub> , 24.7 %  
24  
25 impaired FEF<sub>25-75</sub> % and 66.1% showed reversibility to bronchodilator (31) suggesting  
26  
27 that these alterations may indicate a “pre-asthmatic” status which can gradually evolve to  
28  
29 clinically demonstrated asthma with the progression of the "atopic march". This could  
30  
31 have therapeutic implications; however, in our study and considering the dissociated  
32  
33 conditions frequency and severity, we could not reproduce similar findings because the  
34  
35 reversibility obtained between groups was not significant. This is probably due because  
36  
37 the bronchodilator response was rated using not only patients presenting obstructive  
38  
39 defects but also those with alterations in FVC only.  
40  
41  
42  
43  
44

45  
46 The abnormality in lung function was independent of the atopy condition: whilst a higher  
47  
48 prevalence of allergic sensitization was observed in patients with severe rhinitis (Table  
49  
50 2), both phenotypes of rhinitis (allergic and non-allergic), showed similar functional  
51  
52 involvement. Chawes et al. (15) found similar impairment of the specific airway  
53  
54 resistance (sRaw), measured by whole body plethysmography in young children with  
55  
56 allergic and non-allergic rhinitis, although the former ones had significantly higher values  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 of exhaled nitric oxide (FeNO). These findings suggest that the impact of rhinitis on lung  
5  
6 function, in absence of asthma, would be proper to the condition of rhinitis and would not  
7  
8 be associated with its etiology.  
9

10  
11 Rhinitis in pediatric patients have a sub-clinical bronchial disease process that is  
12  
13 proportional to the magnitude of the disease, but the prognosis value of these findings is  
14  
15 not yet determined.  
16  
17

18  
19 It is shown that rhinitis is an independent risk factor for developing asthma (32-35) and  
20  
21 that the use of intranasal steroids can improve the functional defect in children with  
22  
23 allergic rhinitis without asthma (36), but no prospective research establish that patients  
24  
25 with rhinitis and impaired lung function have a higher risk of developing asthma.  
26  
27 Possibly this depends on common genetic factors for a possible progression of rhinitis to  
28  
29 asthma (37,38), which could have an initial sub-clinical expression in intra-thoracic  
30  
31 airway obstruction.  
32  
33

34  
35 These potential diagnostic, prognostic and therapeutic implications are sufficient reasons  
36  
37 to suggest that patients with rhinitis alone should be evaluated for asthma, based on their  
38  
39 clinical history, a careful chest examination and lung function assessment just as  
40  
41 proposed by the ARIA document (1,2). Our findings support the indication of spirometry  
42  
43 only in patients with persistent, moderate and severe degree of rhinitis, making  
44  
45 unnecessary the routine determination in patients with rhinitis classified as mild and  
46  
47 intermittent. This management strategy could contribute to financial savings for public  
48  
49 health, a suggestion which should be confirmed with studies involving a larger sample of  
50  
51 patients and reproducible results with other centers.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Our study has the strength to confirm the asymptomatic impairment of lung function in  
5 children and adolescents with rhinitis, also observed by other authors (13-18,31) and that  
6  
7 data analysis excluded potentially confounding variables. We recognize the limitations  
8  
9 imposed by the clinical classifying degrees of rhinitis, because these can manifest  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Our study has the strength to confirm the asymptomatic impairment of lung function in children and adolescents with rhinitis, also observed by other authors (13-18,31) and that data analysis excluded potentially confounding variables. We recognize the limitations imposed by the clinical classifying degrees of rhinitis, because these can manifest variability over time and be influenced by subjectivity between operators.

In conclusion, this study highlights that impaired lung function appears in a substantial percentage of patients with allergic and non-allergic rhinitis. The involvement was more common in persistent, moderate to severe rhinitis, with no significant differences between these last two degrees of severity. The bronchial involvement was independent of the atopic status suggesting a link between the upper and lower airway diseases beyond the inflammation associated to the allergy status.

Our results also allow us to suggest that subjects with rhinitis and without asthma should be evaluated for their lung function, because this somehow can influence the course of the disease.

## References

1. Bousquet J, Van Cauwenberge P, Khaltaev N, ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. ARIA workshop report. *J Allergy Clin Immunol* 2001;108(5):S147-S334.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). *Allergy* 2008;63:S8-S160.

3. Gentile D, Bartholow A, Valovirta E, Scadding G, Skoner D. Current and future directions in pediatric allergic rhinitis. *J Allergy Clin Immunol: in Practice* 2013; 1:214-26.
4. Sluder G. Asthma as a nasal reflex. *JAMA* 1919;73:589–591.
5. Saranz RJ. Vías aéreas unidas e impacto recíproco entre rinosinusitis y asma. *Alergia Immunol Clin* 2002;19(3):71-77.
6. Cruz A. The “united airways” require an holistic approach to management. *Allergy* 2005; 60: 871-874.
7. Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. *Allergy* 2003; 58: 691-706.
8. Dixon AE. Rhinosinusitis and asthma: the missing link. *Curr Opin Pulmonary Med* 2009;15:19-24.
9. Kariyawasam HH, Rotiroti G. Allergic rhinitis, chronic rhinosinusitis and asthma: unravelling a complex relationship. *Curr Opin Otolaryngol Head Neck Surg* 2013; 21:79–86.
10. Agresta MF, Saranz RJ, Lozano A, Lonzano NA. Relación entre rinitis y asma: ¿Está todo dicho?. *Revista de la Facultad de Ciencias Médicas UNC* 2014; 71(2):111-121.
11. Montoro J, Del Cuvillo A, Mullol J, Molina X, Dávila I, Ferrer M, Jáuregui I, Sastre J, Valero A. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study. *Allergy* 2012; 67: 1437-1442.
12. Valero A, Ferrer M, Sastre J, Navarro AM, Monclus L, Marti-Guadaño E, Herdman M, Dávila I, del Cuvillo A, Colas C, Baro E, Antepará I, Alonso J, Mullol J. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. *J Allergy Clin Immunol* 2007;120:359-65.

- 1  
2  
3  
4 13. Ciprandi G, Cirillo I, Pistorio A. Impact of allergic rhinitis on asthma: effects on  
5  
6 spirometric parameters. *Allergy* 2008;63:255-260.  
7
- 8  
9 14. Ciprandi G, Capasso M. Association of childhood perennial allergic rhinitis with  
10  
11 subclinical airflow limitation. *Clin Exp Allergy* 2010; 40: 398-402.  
12
- 13  
14 15. Chawes BL. Upper and lower airway pathology in young children with allergic- and non-  
15  
16 allergic rhinitis. *Dan Med Bull* 2011; 58(5):1-23.  
17
- 18  
19 16. Mohammad Y, Shaaban R, Ibrahim M, Ismail M. Lung function changes in non-  
20  
21 asthmatic allergic rhinitis patients: a case series. *Prim Care Respir J* 2011; 20(4): 454-  
22  
23 456.
- 24  
25 17. Ianiero L, Saranz RJ, Lozano NA, Lozano A, Sasia LV, Ramírez M, Cuestas E. Analysis  
26  
27 of the flow-volume curve in children and adolescents with allergic rhinitis without  
28  
29 asthma. *Arch Argent Pediatr* 2013;111:322-327.  
30
- 31  
32 18. Jeffery CC, Bhutani M, Vliagoftis H, Wright ED, Seikaly H, Côté DW. Association  
33  
34 between allergic rhinitis and asthma in a Northern Alberta cohort. *J Otolaryngol Head*  
35  
36 *Neck Surg* 2013;42:58.
- 37  
38 19. Capasso M, Varricchio A, Ciprandi G. Impact of allergic rhinitis on asthma in children:  
39  
40 effects on bronchodilation test. *Allergy* 2010; 65:264-268.  
41
- 42  
43 20. Ciprandi G, Signori A, Tosca MA, Cirillo I. Bronchodilation test in patients with allergic  
44  
45 rhinitis. *Allergy* 2011; 66: 694–698.
- 46  
47 21. Bousquet J, Fokkens W, Burney P, Durham SR, Bachert C, Akdis CA et al. Important  
48  
49 research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper.  
50  
51 *Allergy* 2008; 63: 842-853.  
52
- 53  
54 22. Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and  
55  
56 perception of allergic and nonallergic rhinitis in Belgium. *Allergy* 2006; 61: 693-698.  
57
- 58  
59 23. Cox L, Williams B, Sicherer S, Oppenheimer J, Sher L, Hamilton R, Golden D. Pearls and  
60  
61 pitfalls of allergy diagnostic testing: report from the American College of Allergy,  
62  
63  
64  
65

- 1  
2  
3  
4 Asthma and Immunology/ American Academy of Allergy, Asthma and Immunology  
5  
6 Specific IgE Test Task Force. *Ann Allergy Asthma Immunol.* 2008;101:580-592.  
7  
8  
9 24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.  
10  
11 Standardisation of spirometry. *Eur Respir J* 2005; 26:319-338.  
12  
13 25. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume  
14  
15 curve. Normal standards, variability, and effects of age. *Am Rev Respir Dis* 1976;113:  
16  
17 587-600.  
18  
19 26. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative  
20  
21 strategies for lung function tests. *Eur Respir J* 2005; 26:948-968.  
22  
23 27. Bates D, Maechler M, Bolker B and Walker S. (2013). lme4: Linear mixed-effects  
24  
25 models using Eigen and S4. R package version 1.0-4. [http://CRAN.R-](http://CRAN.R-project.org/package=lme4)  
26  
27 [project.org/package=lme4](http://CRAN.R-project.org/package=lme4)  
28  
29  
30 28. R Core Team (2013). R: A language and environment for statistical computing. R  
31  
32 Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>.  
33  
34 29. Di Rienzo J.A., Casanoves F., Balzarini M.G., Gonzalez L., Tablada M., Robledo C.W.  
35  
36 InfoStat versión 2013. Grupo InfoStat, FCA, Universidad Nacional de Córdoba,  
37  
38 Argentina. URL <http://www.infostat.com.ar>  
39  
40  
41 30. Kim SW, Han DH, Lee SJ, Lee CH, Rhee CS. Bronchial hyperresponsiveness in pediatric  
42  
43 rhinitis patients: The difference between allergic and nonallergic rhinitis. *Am J Rhinol*  
44  
45 *Allergy* 2013;27:63-68.  
46  
47  
48 31. Ciprandi G, Signori A, Tosca MA, and Cirillo I. Spirometric abnormalities in patients  
49  
50 with allergic rhinitis: indicator of an asthma march? *Am J Rhinol Allergy* 2011; 25:e181-  
51  
52 e185.  
53  
54  
55 32. Scadding G, Walker A. Poor asthma control? – Then look up the nose. The importance of  
56  
57 co-morbid rhinitis in patients with asthma. *Prim Care Respir J* 2012; 21: 222-228.  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 33. Leynaert B, Bousquet J, Neukirch C, Korobaeff M, Liard R, Neukirch F. Perennial  
5  
6 rhinitis: an independent risk factor for asthma in nonatopic subjects. Results from the  
7  
8 European Community Respiratory Health Survey. *J Allergy Clin Immunol* 1999;104:301-  
9  
10 304.  
11  
12  
13 34. Eriksson J, Bjerg A, Lötvall J, Wennergren G, Rönmark E, Torén K, Lundbäck B.  
14  
15 Rhinitis phenotypes correlate with different symptom presentation and risk factor patterns  
16  
17 of asthma. *Respir Med* 2011;105; 1611-1621.  
18  
19  
20 35. Higuchi O, Adachi Y, Itazawa T, Ito Y, Yoshida K, Ohya Y, et al. Rhinitis has an  
21  
22 association with asthma in school children. *Am J Rhinol Allergy* 2013;27;22-25.  
23  
24  
25 36. Kessel A. The impact of intranasal corticosteroids on lung function in children with  
26  
27 allergic rhinitis. *Pediatr Pulmonol* 2014; 49:932-937.  
28  
29  
30 37. Bouzigon E, Forabosco P, Koppelman GH, Cookson WO, Dizier MH, Duffy DL, et al.  
31  
32 Meta-analysis of 20 genome wide linkage studies evidenced new regions linked to  
33  
34 asthma and atopy. *Eur J Hum Genet* 2010; 18:700-706.  
35  
36  
37 38. Boulay MV, Morin A, Laprise C, Boulet LP. Asthma and rhinitis: what is the  
38  
39 relationship? *Curr Opin Allergy Clin Immunol* 2012,12:449-454.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## FIGURES AND TABLES

Table 1: Demographic characteristics of patients with rhinitis according to the frequency of symptoms classified by the mARIA\* criteria.

	Total (n=189)	Intermittent rhinitis (n=48)	Persistent rhinitis (n=141)	p- value
Age (years)	11.36±3.37 (5.08-18.67)	11.41 ± 3.42 ( 6.08-18.67 )	11.34 ± 3.36 ( 5.08-18.00 )	0.904
Weight (kg)	42.40±15.84 (17.00-92.00)	41.95 ± 13.70 ( 19.00-75.50 )	42.56 ± 16.55 ( 17.00-92.00 )	0.819
Height (mts)	1.47±0.18 (1.12-1.88)	1.48 ± 0.17 ( 1.14-1.80 )	1.47 ± 0.19 ( 1.12-1.88 )	0.723
Body mass index	18.75±3.40 (11.24-30.36)	18.53 ± 2.84 ( 14.48-25.88 )	18.83 ± 3.57 ( 11.24-30.36 )	0.603
Onset age of rhinitis (years)	6.06±3.74 (0.50-16.00)	5.90 ± 4.18 ( 0.5 – 15 )	6.11 ± 3.59 ( 0.5 – 16 )	0.742
Duration of rhinitis (months)	63.58±41.35 (3.00-204.00)	66.04 ± 44.88 ( 9.00-184.00 )	62.74 ± 40.21 ( 3.00-204.00 )	0.634
Percent of life affected	47.25±26.08 (3.03-96.00)	49.36 ± 28.26 ( 5.08-94.64 )	46.54 ± 25.36 ( 3.03-96.00 )	0.518
Atopic status	76%	83%	73%	0.140
Males	54%	56%	53%	0.713

Data are expressed as mean± DS, in parenthesis: range. \* mARIA: Allergic Rhinitis and its Impact on Asthma modified.



Tabla 2: Demographic characteristics of patients with rhinitis according to the severity of symptoms classified by the mARIA\* criteria.

	Total (n=189)	Mild rhinitis (n=65)	Moderate rhinitis (n=77)	Severe rhinitis (n=47)	p- value**
Age (years)	11.36±3.37 (5.08-18.67)	10.30 <sup>a</sup> ± 3.36 ( 5.42 - 18.00 )	11.28 <sup>a</sup> ± 2.99 ( 5.08 - 18.67 )	12.94 <sup>b</sup> ± 3.42 ( 6.92 - 18.00 )	0.0001
Weigh (kg)	42.40±15.84 (17.00-92.00)	38.10 <sup>b</sup> ± 14.68 ( 17.00 - 77.00 )	43.51 <sup>a</sup> ± 15.25 ( 17.30 - 85.70 )	46.54 <sup>a</sup> ± 17.19 ( 19.00 - 92.00 )	0.014
Heigh (mts)	1.47±0.18 (1.12-1.88)	1.42 <sup>b</sup> ± 0.17 ( 1.12 - 1.73 )	1.49 <sup>a</sup> ± 0.17 ( 1.13 - 1.81 )	1.53 <sup>a</sup> ± 0.19 ( 1.14 - 1.88 )	0.003
Body mass index	18.75±3.40 (11.24-30.36)	18.26 ± 3.38 ( 11.24 - 27.58 )	18.95 ± 3.52 ( 12.64 - 30.36 )	19.11 ± 3.20 ( 13.23 - 26.59 )	0.345
Onset age of rhinitis (years)	6.06±3.74 (0.50-16.00)	5.76 ± 3.52 ( 0.50 - 15 )	6.02 ± 3.75 ( 0.50 - 16 )	6.55 ± 4.03 ( 1.00 - 15.5 )	0.541
Duration of rhinitis (months)	63.58±41.35 (3.00-204.00)	54.54 <sup>b</sup> ± 37.52 ( 3.00 - 184.00 )	63.17 <sup>b</sup> ± 39.69 ( 6.00 - 156.00 )	76.77 <sup>a</sup> ± 46.18 ( 9.00 - 204.00 )	0.018
Percent of life affected	47.25±26.08 (3.03-96.00)	45.11 ± 25.37 ( 3.03 - 94.00 )	47.59 ± 27.17 ( 5.08 - 96.00 )	49.67 ± 25.54 ( 7.63 - 94.44 )	0.655
Atopic status	76%	65 <sup>b</sup> %	75 <sup>b</sup> %	91 <sup>a</sup> %	0.003
Males	54%	54%	60%	45%	0.263

Data are expressed as mean± DS, in parenthesis: range.

\* mARIA: Allergic Rhinitis and its Impact on Asthma modified.

\*\* a vs b (p <0.05).

Tabla 3: Distribution of patients with impairment in lung function, abnormalities in different spirometric parameters and bronchodilator response according to frequency and severity of rhinitis classified by the mARIA\* criteria.

	Intermittent rhinitis (n=48)	Persistent rhinitis (n=141)	p value	p value for atopy	Mild rhinitis (n=65)	Moderate rhinitis (n=77)	Severe rhinitis (n=47)	p value**	p value for atopy
FVC (% abnormal <80%)	3%	7%	0.182	0.009	1% <sup>b</sup>	8% <sup>a</sup>	10% <sup>a</sup>	0.009	0.025
FEV1 (% abnormal <80%)	5%	9%	0.319	0.031	1% <sup>b</sup>	9% <sup>a</sup>	15% <sup>a</sup>	0.001	0.069
FEV1/FVC (% abnormal <80%)	6%	8%	0.671	0.379	5%	8%	9%	0.614	0.285
FEF 25-75% (% abnormal <65%)	5%	9%	0.322	0.043	3%	10%	10%	0.136	0.079
Patients with impairment in lung function (%)	11%	25%	0.026	0.157	9% <sup>b</sup>	23% <sup>a</sup>	36% <sup>a</sup>	0.005	0.538
Patients with positive bronchodilator response (%)	4%	9%	0.186	0.468	3%	9%	14%	0.057	0.742

\* mARIA: Allergic Rhinitis and its Impact on Asthma modified.

\*\* a vs b (p <0.05).